Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2026-03-12 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including share pledges, stock lending, and market sales by major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-12 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares' (주식 담보제공 계약). This type of disclosure, which details the collateralization of shares by a major shareholder to secure debt, falls under the category of capital and financing updates as it relates to the company's capital structure and financial obligations. It does not fit into specific categories like M&A, dividends, or earnings releases, making 'CAP' the most accurate classification for a financing-related regulatory update.
2026-03-06 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares by the Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). It details changes in collateralized shares, loan amounts, and contract terms. Since this is a specific regulatory disclosure regarding capital structure and share pledging, it falls under the 'Regulatory Filings' category as it does not fit into more specific categories like 'Director's Dealing' (which is for individual trades) or 'Share Issue' (which is for new capital).
2026-03-05 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Change in Collateral Provision Contract by the Largest Shareholder'. It details specific financial agreements, collateral amounts, and debt obligations. This type of disclosure is a standard regulatory requirement for listed companies to report changes in share pledges or collateralization, which falls under the 'Capital/Financing Update' category as it relates to the company's capital structure and financing activities.
2026-03-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider trading or changes in share ownership by company directors and major shareholders. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers personal share transactions by company executives.
2026-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by insiders or major shareholders to report changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it details transactions and ownership changes by a major shareholder (Gem & Company) in the issuing company (GemVax & KAEL).
2026-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.